Developer docs
API playgroundTry for free, no card

Search company profiles

Link Biologics

Full company profile

uuid000s1a7

Namestring
Link Biologics
Legal namestring
Link Biologics Limited
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Link Biologics Limited is a preclinical-stage biotechnology company headquartered in London, UK, that develops protein biologic therapeutics based on TSG-6 (Tumor Necrosis Factor-stimulated Gene-6). The company was spun out of the University of Manchester in June 2021 to translate decades of academic research by co-founders Professor Tony Day and Dr. Caroline Milner into clinical assets. Its technology centres on Link_TSG6, the isolated Link module domain of human TSG-6, which is engineered to deliver multi-pathway modulation combining anti-inflammatory, tissue-protective, and tissue-reparative activity rather than blocking a single disease pathway. The pipeline comprises LB001 (Dry Eye Disease), LB002 (Osteoarthritis), LB003 (an undisclosed musculoskeletal indication in discovery), and LB004 (Wet AMD, designed for subcutaneous administration to avoid intraocular injection); pre-clinical data include corneal protection in DED models superior to Restasis and cartilage-protective effects in OA models.

Short descriptiontext

Link Biologics is a UK preclinical-stage biotech spun out from the University of Manchester in 2021, developing Link_TSG6 protein biologics targeting Dry Eye Disease, Wet AMD, and Osteoarthritis, with its lead DED programme backed by a £200M+ Théa Group partnership.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
protein therapeutics, anti-inflammatory biologics, tissue-protective therapies, ophthalmology drug development, TSG-6 biologics
Industry4 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic development and commercialization
TypeOne Time License
Description

Pre-revenue biotech company developing protein biologics for inflammatory and degenerative diseases. Revenue will be generated through pharmaceutical product sales upon successful clinical development and regulatory approval.

linkbiologics.co.uk
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Link Biologics develops and commercialises protein biologics based on Link_TSG6, the isolated Link module domain of human TSG-6, for the treatment of inflammatory and degenerative diseases. Its pipeline centres on LB001 (Dry Eye Disease), LB002 (Osteoarthritis), LB003 (undisclosed musculoskeletal indication) and LB004 (Wet Age-related Macular Degeneration), combining anti-inflammatory, tissue-protective and tissue-reparative activity through multi-pathway modulation. The company monetises this pipeline through development and commercialisation partnerships with established pharmaceutical companies, with Théa Group as lead partner for LB001 in a fully funded >£200M deal.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Link_TSG6 suppressed production of enzymes implicated in cartilage damage in OA models
+4 more records
Product overview1 text field

Link Biologics is pioneering the development of protein biologics that harness the protective biology of TSG-6 (Tumor Necrosis Factor-stimulated Gene-6). The company's core product is Link_TSG6, a recombinant human protein biologic comprising the isolated Link module domain from human TSG-6. This technology underlies the entire pipeline portfolio including LB001 (Dry Eye Disease), LB002 (Osteoarthritis), LB004 (Wet AMD), and LB003 (undisclosed musculoskeletal indication). Unlike conventional therapies that block single pathways, these biologics modulate multiple aspects of disease by combining anti-inflammatory, tissue-protective, and tissue-reparative properties, acting as a biological rheostat rather than a simple on/off switch. The lead programme LB001 is partnered with Théa Group in a >£200M deal and expected to enter clinical trials in 2027.

Product and service5 records
1Link_TSG6 (protein biologic)
CategoryCore protein biologic platform
Description

Novel protein biologic consisting of the isolated Link module domain from human TSG-6, designed to treat inflammatory and degenerative diseases through multi-pathway modulation combining anti-inflammatory, tissue-protective, and tissue-reparative properties. Intended to act as a biological rheostat fine-tuning intrinsic pathways rather than as a single-pathway blocker, for development partners and licensees in pharmaceutical and biotech companies.

2LB001 (Dry Eye Disease programme)
CategoryOphthalmology therapeutic candidate
Description

Lead Link_TSG6-based ophthalmology programme for the treatment of Dry Eye Disease in preclinical development, partnered with Théa Group and validated by FDA-confirmed Phase 3-enabling Phase 1/2 trial design, GLP toxicology completion in two species and GMP production at clinical scale. Aimed at the global Dry Eye Disease market (~350 million patients) with significant unmet need.

3LB002 (Osteoarthritis programme)
CategoryMusculoskeletal therapeutic candidate
Description

Link_TSG6-based musculoskeletal programme for the treatment of Osteoarthritis in preclinical development, demonstrating disease-modifying potential in preclinical models: suppression of cartilage-damaging enzymes and reduction in cartilage breakdown and touch-evoked pain behaviour. Aimed at patients with Osteoarthritis (~365 million globally), where no disease-modifying treatment currently exists.

4LB004 (Wet Age-related Macular Degeneration programme)
CategoryOphthalmology therapeutic candidate
Description

Link_TSG6-based ophthalmology programme for Wet Age-related Macular Degeneration in preclinical development, differentiated by potential subcutaneous administration that would avoid the burden of intraocular injections. Part of Link Biologics' multi-billion-dollar ophthalmology focus.

5LB003 (disclosed musculoskeletal programme)
CategoryMusculoskeletal therapeutic candidate
Description

Link_TSG6-based musculoskeletal programme in discovery stage, targeting an undisclosed musculoskeletal indication and extending the platform beyond LB002's Osteoarthritis focus.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Théa Group
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2027-01-01
Description

Fully funded >£200M partnership with Théa Group for the DED programme (LB001). Théa Group is a leading ophthalmology company and provides validation for Link Biologics' approach. Céline Olmiere, Head of Théa Open Innovation, serves on Link Biologics' Board.

linkbiologics.co.uk
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-05
Description

Link Biologics was spun-out from the University of Manchester in June 2021. The company acquired full ownership of key patent rights for Link_TSG6 originally developed at the University of Manchester. Research collaboration on osteoarthritis with academic researchers including Professor Tony Day and Caroline Milner.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-13
Description

Research collaboration on Dry Eye Disease preclinical studies with researchers from Seoul National University College of Medicine, including Dr Joo Youn Oh as corresponding author of published research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Oculis is a clinical-stage ophthalmology biotech developing novel therapies for DED and other retinal diseases, including a biologic eye drop (licaminlimab) and OCS-05 for neuroprotection. Directly comparable to Link Biologics in indication focus (DED, AMD), modality (biologics), and stage of clinical translation.

TypeDirect peer
Description

Novaliq is an ophthalmology-focused biotech developing water-free topical therapies for DED (e.g., CyclASol/Vevye, perfluorohexyloctane-based products). Directly comparable to Link Biologics' LB001 DED programme in indication and therapeutic positioning, although differentiated by delivery technology.

TypeDirect peer
Description

OcuTerra is developing innovative ophthalmic therapies including OTT166, a DED treatment being advanced through clinical development. Direct peer in DED indication and stage; notably, Dr. Majid Anderesi (Link Biologics' Senior Clinical Lead) is a former VP of Clinical Development at OcuTerra, evidencing deep personnel overlap.

TypeDirect peer
Description

Sylentis is a clinical-stage ophthalmology biotech developing RNAi-based therapies for DED (tivanisiran) and other ocular indications. Directly comparable in DED indication focus and clinical-stage positioning, with a differentiated oligonucleotide rather than protein-biologic mechanism.

TypeDirect peer
Description

Kala Bio is a clinical-stage biopharmaceutical company developing novel biologics for ophthalmic diseases, with a focus on rare and serious front- and back-of-eye conditions. Directly comparable in modality (protein biologics) and indication focus (ophthalmology), and similar preclinical/early-clinical stage development profile.

TypeDirect peer
Description

Tarsus is a commercial-stage ophthalmology company with lead therapy Xdemvy for Demodex blepharitis and a pipeline including DED and other ocular surface programmes. Comparable in DED/ocular surface disease focus and ophthalmology commercial positioning, although more advanced commercially.

TypeDirect peer
Description

Biosplice developed lorecivivint, a Phase 3-stage DMOAD candidate for knee OA, and has a broader pipeline in osteoarthritis and musculoskeletal disease. Directly comparable to Link Biologics' LB002 OA programme in indication, disease-modifying positioning, and clinical-stage development.

TypeEmerging player
Description

HanAll is a clinical-stage biopharma developing novel biologics for autoimmune and inflammatory diseases, with ophthalmology and rare disease programs. Comparable in modality (protein biologics), anti-inflammatory mechanism, and emerging-stage development of inflammation-focused therapeutics.

TypeEmerging player
Description

Oxular is an ocular therapeutics biotech developing sustained-release drug delivery technologies for retinal diseases, including diabetic macular edema and AMD. Comparable in ophthalmology focus and emerging-stage retinal disease programmes, with a differentiated delivery rather than biologic mechanism.

10Artios Pharma
TypeOthers
Description

Artios is a clinical-stage oncology biotech developing DNA damage response (DDR) inhibitors. While not directly comparable in indication, Artios is highly relevant contextually: Dr. Niall Martin (new Link Biologics board appointee) was co-founder and former CEO of Artios, and the company has raised >£300M, providing a useful comp for capital and operational scaling.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Link Biologics

Biopharmaceuticalslinkbiologics.co.uk

Link Biologics is a UK preclinical-stage biotech spun out from the University of Manchester in 2021, developing Link_TSG6 protein biologics targeting Dry Eye Disease, Wet AMD, and Osteoarthritis, with its lead DED programme backed by a £200M+ Théa Group partnership.

What Link Biologics does

Link Biologics Limited is a preclinical-stage biotechnology company headquartered in London, UK, that develops protein biologic therapeutics based on TSG-6 (Tumor Necrosis Factor-stimulated Gene-6). The company was spun out of the University of Manchester in June 2021 to translate decades of academic research by co-founders Professor Tony Day and Dr. Caroline Milner into clinical assets. Its technology centres on Link_TSG6, the isolated Link module domain of human TSG-6, which is engineered to deliver multi-pathway modulation combining anti-inflammatory, tissue-protective, and tissue-reparative activity rather than blocking a single disease pathway. The pipeline comprises LB001 (Dry Eye Disease), LB002 (Osteoarthritis), LB003 (an undisclosed musculoskeletal indication in discovery), and LB004 (Wet AMD, designed for subcutaneous administration to avoid intraocular injection); pre-clinical data include corneal protection in DED models superior to Restasis and cartilage-protective effects in OA models.

Link Biologics firmographics

Firmographics
Name
Link Biologics
Legal name
Link Biologics Limited
Website
https://linkbiologics.co.uk
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Link Biologics is a UK preclinical-stage biotech spun out from the University of Manchester in 2021, developing Link_TSG6 protein biologics targeting Dry Eye Disease, Wet AMD, and Osteoarthritis, with its lead DED programme backed by a £200M+ Théa Group partnership.
Ownership category
akta.pro rank

Link Biologics industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Protein therapeutics
  • Anti-inflammatory biologics
  • Tissue-protective therapies
  • Ophthalmology drug development
  • TSG-6 biologics

Where Link Biologics is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Link Biologics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Therapeutic development and commercialization: Pre-revenue biotech company developing protein biologics for inflammatory and degenerative diseases. Revenue will be generated through pharmaceutical product sales upon successful clinical development and regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Link Biologics product offering

Product offering

Core offering

Link Biologics develops and commercialises protein biologics based on Link_TSG6, the isolated Link module domain of human TSG-6, for the treatment of inflammatory and degenerative diseases. Its pipeline centres on LB001 (Dry Eye Disease), LB002 (Osteoarthritis), LB003 (undisclosed musculoskeletal indication) and LB004 (Wet Age-related Macular Degeneration), combining anti-inflammatory, tissue-protective and tissue-reparative activity through multi-pathway modulation. The company monetises this pipeline through development and commercialisation partnerships with established pharmaceutical companies, with Théa Group as lead partner for LB001 in a fully funded >£200M deal.

Product overview

Link Biologics is pioneering the development of protein biologics that harness the protective biology of TSG-6 (Tumor Necrosis Factor-stimulated Gene-6). The company's core product is Link_TSG6, a recombinant human protein biologic comprising the isolated Link module domain from human TSG-6. This technology underlies the entire pipeline portfolio including LB001 (Dry Eye Disease), LB002 (Osteoarthritis), LB004 (Wet AMD), and LB003 (undisclosed musculoskeletal indication). Unlike conventional therapies that block single pathways, these biologics modulate multiple aspects of disease by combining anti-inflammatory, tissue-protective, and tissue-reparative properties, acting as a biological rheostat rather than a simple on/off switch. The lead programme LB001 is partnered with Théa Group in a >£200M deal and expected to enter clinical trials in 2027.

Differentiator

Problem solved

Functional benefit

Products and services

  • Link_TSG6 (protein biologic) Novel protein biologic consisting of the isolated Link module domain from human TSG-6, designed to treat inflammatory and degenerative diseases through multi-pathway modulation combining anti-inflammatory, tissue-protective, and tissue-reparative properties. Intended to act as a biological rheostat fine-tuning intrinsic pathways rather than as a single-pathway blocker, for development partners and licensees in pharmaceutical and biotech companies.
  • LB001 (Dry Eye Disease programme) Lead Link_TSG6-based ophthalmology programme for the treatment of Dry Eye Disease in preclinical development, partnered with Théa Group and validated by FDA-confirmed Phase 3-enabling Phase 1/2 trial design, GLP toxicology completion in two species and GMP production at clinical scale. Aimed at the global Dry Eye Disease market (~350 million patients) with significant unmet need.
  • LB002 (Osteoarthritis programme) Link_TSG6-based musculoskeletal programme for the treatment of Osteoarthritis in preclinical development, demonstrating disease-modifying potential in preclinical models: suppression of cartilage-damaging enzymes and reduction in cartilage breakdown and touch-evoked pain behaviour. Aimed at patients with Osteoarthritis (~365 million globally), where no disease-modifying treatment currently exists.
  • LB004 (Wet Age-related Macular Degeneration programme) Link_TSG6-based ophthalmology programme for Wet Age-related Macular Degeneration in preclinical development, differentiated by potential subcutaneous administration that would avoid the burden of intraocular injections. Part of Link Biologics' multi-billion-dollar ophthalmology focus.
  • LB003 (disclosed musculoskeletal programme) Link_TSG6-based musculoskeletal programme in discovery stage, targeting an undisclosed musculoskeletal indication and extending the platform beyond LB002's Osteoarthritis focus.

Quantifiable outcome

  • Link_TSG6 suppressed production of enzymes implicated in cartilage damage in OA models
  • +4 more outcomes

Companies that use Link Biologics

Customer profile

Segments2 records

Ideal customer profiles1 record

Link Biologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Link Biologics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Théa GroupcoreStrategic or Co-development Partner · 1 January 2027Fully funded >£200M partnership with Théa Group for the DED programme (LB001). Théa Group is a leading ophthalmology company and provides validation for Link Biologics' approach. Céline Olmiere, Head of Théa Open Innovation, serves on Link Biologics' Board.
  • University of ManchestercoreStrategic or Co-development Partner · 5 June 2023Link Biologics was spun-out from the University of Manchester in June 2021. The company acquired full ownership of key patent rights for Link_TSG6 originally developed at the University of Manchester. Research collaboration on osteoarthritis with academic researchers including Professor Tony Day and Caroline Milner.
  • Seoul National University College of MedicineminorStrategic or Co-development Partner · 13 January 2022Research collaboration on Dry Eye Disease preclinical studies with researchers from Seoul National University College of Medicine, including Dr Joo Youn Oh as corresponding author of published research.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Link Biologics competitors and assessment

Company assessment

Direct peers

  • Oculis Holding AG: Oculis is a clinical-stage ophthalmology biotech developing novel therapies for DED and other retinal diseases, including a biologic eye drop (licaminlimab) and OCS-05 for neuroprotection. Directly comparable to Link Biologics in indication focus (DED, AMD), modality (biologics), and stage of clinical translation.
  • Novaliq GmbH: Novaliq is an ophthalmology-focused biotech developing water-free topical therapies for DED (e.g., CyclASol/Vevye, perfluorohexyloctane-based products). Directly comparable to Link Biologics' LB001 DED programme in indication and therapeutic positioning, although differentiated by delivery technology.
  • OcuTerra Therapeutics: OcuTerra is developing innovative ophthalmic therapies including OTT166, a DED treatment being advanced through clinical development. Direct peer in DED indication and stage; notably, Dr. Majid Anderesi (Link Biologics' Senior Clinical Lead) is a former VP of Clinical Development at OcuTerra, evidencing deep personnel overlap.
  • Sylentis (PharmaMar group): Sylentis is a clinical-stage ophthalmology biotech developing RNAi-based therapies for DED (tivanisiran) and other ocular indications. Directly comparable in DED indication focus and clinical-stage positioning, with a differentiated oligonucleotide rather than protein-biologic mechanism.
  • Kala Bio: Kala Bio is a clinical-stage biopharmaceutical company developing novel biologics for ophthalmic diseases, with a focus on rare and serious front- and back-of-eye conditions. Directly comparable in modality (protein biologics) and indication focus (ophthalmology), and similar preclinical/early-clinical stage development profile.
  • Tarsus Pharmaceuticals: Tarsus is a commercial-stage ophthalmology company with lead therapy Xdemvy for Demodex blepharitis and a pipeline including DED and other ocular surface programmes. Comparable in DED/ocular surface disease focus and ophthalmology commercial positioning, although more advanced commercially.
  • Biosplice Therapeutics (formerly Samumed): Biosplice developed lorecivivint, a Phase 3-stage DMOAD candidate for knee OA, and has a broader pipeline in osteoarthritis and musculoskeletal disease. Directly comparable to Link Biologics' LB002 OA programme in indication, disease-modifying positioning, and clinical-stage development.

Emerging players

  • HanAll Biopharma: HanAll is a clinical-stage biopharma developing novel biologics for autoimmune and inflammatory diseases, with ophthalmology and rare disease programs. Comparable in modality (protein biologics), anti-inflammatory mechanism, and emerging-stage development of inflammation-focused therapeutics.
  • Oxular Limited: Oxular is an ocular therapeutics biotech developing sustained-release drug delivery technologies for retinal diseases, including diabetic macular edema and AMD. Comparable in ophthalmology focus and emerging-stage retinal disease programmes, with a differentiated delivery rather than biologic mechanism.

Others

  • Artios Pharma: Artios is a clinical-stage oncology biotech developing DNA damage response (DDR) inhibitors. While not directly comparable in indication, Artios is highly relevant contextually: Dr. Niall Martin (new Link Biologics board appointee) was co-founder and former CEO of Artios, and the company has raised >£300M, providing a useful comp for capital and operational scaling.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Link Biologics social profiles

Digital presence

Link Biologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Link Biologics leadership team

Management profile

Number of profiles

Profiles10 records

Link Biologics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Link Biologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Link Biologics

What does Link Biologics do?

Link Biologics develops and commercialises protein biologics based on Link_TSG6, the isolated Link module domain of human TSG-6, for the treatment of inflammatory and degenerative diseases. Its pipeline centres on LB001 (Dry Eye Disease), LB002 (Osteoarthritis), LB003 (undisclosed musculoskeletal indication) and LB004 (Wet Age-related Macular Degeneration), combining anti-inflammatory, tissue-protective and tissue-reparative activity through multi-pathway modulation. The company monetises this pipeline through development and commercialisation partnerships with established pharmaceutical companies, with Théa Group as lead partner for LB001 in a fully funded >£200M deal.

Is Link Biologics a public or private company?

Link Biologics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Link Biologics founded?

Link Biologics was founded in 2021. It employs 1 to 10 people.

Where is Link Biologics based?

Link Biologics is headquartered in London, United Kingdom, in the Europe region.

How does Link Biologics make money?

One revenue line is on record: therapeutic development and commercialization.

Who are Link Biologics's main competitors?

Direct peers on record are Oculis Holding AG, Novaliq GmbH, OcuTerra Therapeutics, Sylentis (PharmaMar group), Kala Bio, Tarsus Pharmaceuticals and Biosplice Therapeutics (formerly Samumed). Emerging players are HanAll Biopharma and Oxular Limited. Artios Pharma is listed as an others.

Does Link Biologics have an API?

No public API is recorded for Link Biologics.

What industry is Link Biologics in?

Link Biologics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialLink Biologics Completes IND-Enabling Preclinical Programme For LB001, A First-In-Class Novel Therapy For Dry Eye DiseaseLink Biologics completed its IND-enabling preclinical programme for LB001, a TSG-6-based eye drop for dry eye disease, with repeat-dose toxicology studies showing favourable tolerability. The company also finished two GMP runs to supply planned clinical studies, keeping the IND submission on track for Q1 2027.GlobeNewswireLink Biologics completes IND-enabling preclinical programme for LB001, a first-in-class novel therapy for dry eye diseaseLink Biologics completed its IND-enabling preclinical programme for LB001, a TSG-6-based eye drop for dry eye disease, with repeat-dose toxicology studies showing favourable tolerability. Manufacturing scale-up is complete, and the IND submission is on track for Q1 2027, followed by a Phase 1/2 clinical study.pharmaphorumChanging Faces: Board of Directors and Advisory Boards, February 2026In February 2026, several pharma and biotech companies appointed new board members, including Kurt Hilzinger as chairman of Inceptua Group and Dr Freda Lewis-Hall joining Helus Pharma's board. The appointments brought expertise from executives like Dr Niall Martin and Kevin Pojasek, with some companies adding scientific advisors.BioWorldEyes are first prize for newco Link BiologicsLink Biologics, a newco spun out of the University of Manchester in 2021, was founded by Reuben Dawkins and scientists Tony Day and Caroline Milner. The company's pipeline is based on TSG-6 biology, with four programs across three indications.